Trial reportThe American journal of tropical medicine and hygiene2009
Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites.
Trial report in The American journal of tropical medicine and hygiene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review.BMC infectious diseases · 2021Pooled it
- Trial
- Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs.The American journal of tropical medicine and hygiene · 2022Article
- Liver Enzyme Elevations inThe American journal of tropical medicine and hygiene · 2020Article
- Safety Considerations for Malaria Volunteer Infection Studies: A Mini-Review.The American journal of tropical medicine and hygiene · 2020Review
- The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study.The American journal of tropical medicine and hygiene · 2018Observational
- Controlled Human Malaria Infection: Applications, Advances, and Challenges.Infection and immunity · 2018Review
- DNA microstructure influences selective binding of small molecules designed to target mixed-site DNA sequences.Nucleic acids research · 2017Article
- External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance.PloS one · 2014Article
- A research agenda for malaria eradication: drugs.PLoS medicine · 2011Review
- Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo.PloS one · 2011Article
- Advances in Chagas disease drug development: 2009-2010.Current opinion in infectious diseases · 2010Review
- Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.Antimicrobial agents and chemotherapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We evaluated the causal prophylactic antimalarial activity of a single oral dose of pafuramidine (DB289), an experimental prodrug of active metabolite DB75, in a randomized, double-blind, placebo-controlled, outpatient study. Sixteen healthy volunteers were dosed and challenged in a single cohort. Subjects were randomly assigned to one of three treatment arms: 100 mg pafuramidine eight days before challenge, 100 mg pafuramidine the day before challenge, or placebo. Challenge was by the bites of Plasmodium falciparum-infected Anopheles gambiae. Malaria developed in 15 persons but did not develop in one person in the day -8 pafuramidine treatment arm. Plasma levels of DB75 were lower than expected, and as intended were too low to provide suppressive prophylaxis at the earliest appearance of erythrocytic parasites. We conclude that a single dose of 100 mg pafuramidine does not adequately protect non-immune individuals against P. falciparum and shows no clinically or statistically significant evidence of causal prophylactic activity.
Indexed as
Identifiers
19346370PMC2763313W2146494807What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.